MedTrace Logo

SLC2A1 Variants and Diabetic Nephropathy

NCT01768611 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 449

Last updated 2013-01-16

No results posted yet for this study

Summary

Cells damaged by hyperglycemia are unable to downregulate glucose entrance in presence of high extracellular glucose resulting in intracellular activation of deleterious biochemical pathways. Expression of GLUT-1, the major glucose transporter in mesangial cells, is increased and participates in the induction of diabetic nephropathy. Variants in the gene encoding GLUT-1 (SLC2A1) have been associated to this diabetic complication. The aim of this study was to test whether polymorphisms in SLC2A1 confer susceptibility to diabetic nephropathy in Brazilian type 1 diabetes patients.

Conditions

  • Diabetic Nephropathy.

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Maria L Côrrea-Giannela, Doctor · Hospital Clínicas/Faculdade de Medicina da USP

Eligibility

Min Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01768611 on ClinicalTrials.gov